Determination of RHD zygosity using real-time quantitative PCR

Area of Science:

• Obstetrics and Gynecology
• Genetics
• Molecular Biology

Background:

• RhD incompatibility remains a significant obstetric challenge despite prophylactic treatments.
• Non-invasive prenatal testing using cell-free fetal DNA in maternal plasma has advanced fetal RHD status determination.
• Determining paternal RHD genotype is crucial in high-risk pregnancies for accurate risk assessment of hemolytic disease of the newborn.

Purpose of the Study:

• To demonstrate that a real-time Taqman PCR assay, previously developed for fetal RHD and Y chromosome analysis, can determine paternal RHD genotype.
• To validate the utility of quantitative PCR for assessing fetal RHD status and paternal genotype non-invasively.

Main Methods:

• Utilized a real-time Taqman PCR assay for quantitative analysis of cell-free fetal DNA in maternal plasma.
• Applied the established assay to determine the RHD gene dosage and paternal RHD genotype.
• Leveraged existing technology for non-invasive fetal genetic analysis.

Main Results:

• The developed real-time Taqman PCR assay successfully determined the paternal RHD genotype.
• The assay's capability extends beyond fetal RHD status to include paternal genetic information.
• This method offers a risk-free approach to gain critical genetic insights during pregnancy.

Conclusions:

• The real-time Taqman PCR assay is effective for non-invasively determining paternal RHD genotype from maternal plasma.
• This technique enhances the management of RhD incompatibility by providing crucial paternal genetic information.
• The study highlights the versatility of quantitative PCR in non-invasive prenatal diagnostics.